MCID: RFR010
MIFTS: 49

Refractory Anemia

Categories: Cancer diseases, Blood diseases, Rare diseases

Aliases & Classifications for Refractory Anemia

MalaCards integrated aliases for Refractory Anemia:

Name: Refractory Anemia 59
Refractory Anemia, Without Ringed Sideroblasts, Without Excess Blasts 73
Refractory Anemias 73
Anemia Refractory 55

Characteristics:

Orphanet epidemiological data:

59
refractory anemia
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA98826
UMLS via Orphanet 74 C0002893
MESH via Orphanet 45 D000753
ICD10 via Orphanet 34 D46.7

Summaries for Refractory Anemia

MalaCards based summary : Refractory Anemia, also known as refractory anemia, without ringed sideroblasts, without excess blasts, is related to refractory anemia with excess blasts and chromosome 5q deletion syndrome. An important gene associated with Refractory Anemia is TET2 (Tet Methylcytosine Dioxygenase 2), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Iron and Deferasirox have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are cellular and hematopoietic system

Related Diseases for Refractory Anemia

Diseases related to Refractory Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 refractory anemia with excess blasts 34.0 ASXL1 TET2
2 chromosome 5q deletion syndrome 30.0 EPO TET2
3 anemia, sideroblastic, 1 29.5 ALAS2 TET2
4 myelodysplastic myeloproliferative cancer 29.4 ASXL1 JAK2 TET2
5 myeloproliferative neoplasm 29.3 JAK2 MPL TET2
6 chronic myelomonocytic leukemia 29.0 ASXL1 JAK2 RUNX1 TET2
7 splenomegaly 28.9 EPO JAK2 MPL
8 leukemia 28.7 JAK2 MPL RUNX1
9 acute leukemia 28.6 IL3 JAK2 RUNX1
10 myeloid leukemia 28.4 IL3 JAK2 RUNX1 TET2
11 megakaryocytic leukemia 28.3 IL3 JAK2 RUNX1
12 myelodysplastic syndrome 28.3 ASXL1 EPO IL3 JAK2 MPL RUNX1
13 pancytopenia 28.2 EPO IL3 MPL
14 thrombocytosis 28.1 EPO IL3 JAK2 MPL TET2
15 deficiency anemia 28.1 ALAS2 EPO IL3
16 aplastic anemia 27.8 ASXL1 EPO IL3 MPL TET2
17 polycythemia 26.9 EPO IL3 JAK2 MPL TET2
18 polycythemia vera 26.9 EPO IL3 JAK2 MPL TET2
19 leukemia, acute myeloid 26.8 ASXL1 IL3 JAK2 MPL RUNX1 TET2
20 essential thrombocythemia 26.6 ASXL1 EPO IL3 JAK2 MPL TET2
21 myelofibrosis 26.5 ASXL1 EPO IL3 JAK2 MPL TET2
22 leukemia, chronic myeloid 26.4 EPO IL3 JAK2 MPL RUNX1
23 refractory anemia with excess blasts in transformation 12.2
24 refractory anemia with excess blasts type 2 12.2
25 refractory anemia with excess blasts type 1 12.0
26 pyridoxine-refractory autosomal recessive sideroblastic anemia 11.6
27 acquired idiopathic sideroblastic anemia 11.4
28 aregenerative anemia 11.3
29 anemia, sideroblastic, 2, pyridoxine-refractory 11.0
30 folic acid deficiency anemia 10.3 EPO TET2
31 pyridoxine-responsive sideroblastic anemia 10.3 ALAS2 TET2
32 acquired polycythemia 10.3 EPO JAK2
33 acute erythroid leukemia 10.2 EPO JAK2
34 systemic mastocytosis 10.2 JAK2 TET2
35 atransferrinemia 10.1 ALAS2 TET2
36 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.1
37 thrombocytopenia-absent radius syndrome 10.0 JAK2 MPL
38 core binding factor acute myeloid leukemia 10.0 JAK2 RUNX1
39 blood coagulation disease 10.0 JAK2 MPL
40 pdgfrb-associated chronic eosinophilic leukemia 9.9
41 microcytic anemia 9.9 ALAS2 EPO
42 lymphoblastic leukemia 9.8
43 hemosiderosis 9.8
44 systemic lupus erythematosus 9.8
45 mediastinitis 9.8
46 lupus erythematosus 9.8
47 sideroblastic anemia 9.8
48 siderosis 9.8
49 thymoma 9.8
50 atypical chronic myeloid leukemia 9.7 ASXL1 JAK2 RUNX1

Graphical network of the top 20 diseases related to Refractory Anemia:



Diseases related to Refractory Anemia

Symptoms & Phenotypes for Refractory Anemia

MGI Mouse Phenotypes related to Refractory Anemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.88 ASXL1 EPO JAK2 MPL RUNX1 TET2
2 hematopoietic system MP:0005397 9.87 RUNX1 TET2 ALAS2 ASXL1 EPO JAK2
3 embryo MP:0005380 9.77 ALAS2 EPO JAK2 MPL RUNX1
4 immune system MP:0005387 9.73 ASXL1 EPO JAK2 MPL RUNX1 TET2
5 liver/biliary system MP:0005370 9.55 ASXL1 EPO JAK2 RUNX1 TET2
6 mortality/aging MP:0010768 9.5 ALAS2 ASXL1 EPO JAK2 MPL RUNX1
7 neoplasm MP:0002006 8.92 TET2 ASXL1 JAK2 RUNX1

Drugs & Therapeutics for Refractory Anemia

Drugs for Refractory Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 234)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
2
Deferasirox Approved, Investigational Phase 4,Phase 2 201530-41-8 5493381
3 Chelating Agents Phase 4,Phase 1,Phase 2
4 Iron Chelating Agents Phase 4,Phase 2
5
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
6
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
7
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1 33419-42-0 36462
8
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
9
Cytarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 147-94-4 6253
10
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
11
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
13
Idarubicin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 58957-92-9 42890
14
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
15
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
16
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
17
Daunorubicin Approved Phase 2, Phase 3,Phase 3,Phase 1 20830-81-3 30323
18
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
19
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
20
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
21
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
22
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
23
Magnesium citrate Approved Phase 3 3344-18-1
24
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
25
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
26
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
27
Hydroxyurea Approved Phase 3 127-07-1 3657
28
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
29
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
30
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
31
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
32
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
33
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 104987-11-3 445643 439492
34
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
35
Benzocaine Approved, Investigational Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
36
Thioguanine Approved Phase 3 154-42-7 2723601
37
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
38
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 383414 6400441
39
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
40
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 77-92-9 311
41
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
42
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538 444795
43 tannic acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
45
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
46
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
47 Prednisolone acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
48 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
49 Epoetin alfa Phase 2, Phase 3,Phase 3 113427-24-0
50 Analgesics Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
2 Bowel Preparation and Prokinetics in Capsule Endoscopy Unknown status NCT00275184 Phase 3 Senna;Citramag powder;Metoclopramide
3 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
4 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Unknown status NCT01196715 Phase 3 Darbepoetin alpha;Filgrastim
5 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3 Darbepoetin
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
7 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
8 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
9 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
10 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
11 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
12 Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome Completed NCT00004208 Phase 3 ATG + CSA
13 Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes Completed NCT00003138 Phase 3
14 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
15 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
16 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
17 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
18 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
19 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
20 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
21 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
22 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
23 Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias Recruiting NCT02384122 Phase 2, Phase 3 Octreotide
24 G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Recruiting NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
25 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Recruiting NCT02562443 Phase 3 rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
26 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
27 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
28 A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
29 Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes Unknown status NCT01129739 Phase 2
30 Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome Unknown status NCT00003123 Phase 2 amifostine trihydrate
31 Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00017550 Phase 2
32 Gemtuzumab in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00022321 Phase 2 gemtuzumab ozogamicin
33 Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003827 Phase 2 amifostine trihydrate;cytarabine;topotecan hydrochloride
34 Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome Unknown status NCT00513578 Phase 2
35 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
36 Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003681 Phase 2 amifostine trihydrate
37 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
38 Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
39 Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML Completed NCT00854945 Phase 1, Phase 2 ON 01910.Na
40 A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome Completed NCT00001839 Phase 2 Antithymocyte globulin;Cyclosporine
41 Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies Completed NCT00208923 Phase 2 Busulfan, Cyclophosphamide and Fludarabine
42 Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
43 Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome Completed NCT00005598 Phase 2 amifostine trihydrate;azacitidine
44 Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant Completed NCT01012492 Phase 2 Abatacept
45 Thalidomide in Treating Patients With Myelodysplastic Syndrome Completed NCT00015990 Phase 2 thalidomide
46 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed NCT01165996 Phase 1, Phase 2 decitabine
47 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
48 Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies Completed NCT01175785 Phase 2 fludarabine phosphate;cyclophosphamide;cyclosporine;mycophenolate mofetil
49 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed NCT00462605 Phase 2 entinostat;sargramostim
50 Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome Completed NCT00003415 Phase 1, Phase 2 amifostine trihydrate;topotecan hydrochloride

Search NIH Clinical Center for Refractory Anemia

Genetic Tests for Refractory Anemia

Anatomical Context for Refractory Anemia

MalaCards organs/tissues related to Refractory Anemia:

41
Myeloid, Bone, Bone Marrow, T Cells, Kidney, Testes, Endothelial

Publications for Refractory Anemia

Articles related to Refractory Anemia:

(show top 50) (show all 406)
# Title Authors Year
1
Refractory anemia with ring sideroblasts and thrombocytosis. ( 28401094 )
2017
2
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. ( 29070129 )
2017
3
Severe atypical herpes zoster as an initial symptom of fatal myelodysplastic syndrome with refractory anemia and blast excess (RAEB II). ( 28652792 )
2017
4
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. ( 28188970 )
2017
5
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. ( 27558206 )
2016
6
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. ( 26874914 )
2016
7
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. ( 27479179 )
2016
8
Management of differentiation syndrome in an elderly patient with acute promyelocytic leukemia who subsequently developed refractory anemia with ring sideroblasts. ( 27073113 )
2016
9
Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations. ( 27994837 )
2016
10
Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia. ( 27104191 )
2016
11
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study. ( 27107658 )
2016
12
Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). ( 26855506 )
2016
13
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. ( 26967822 )
2016
14
Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). ( 27771989 )
2016
15
Refractory anemia in human immunodeficiency virus: Expect the unexpected. ( 28217621 )
2016
16
"Irony" of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. ( 27102761 )
2016
17
Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q). ( 28092889 )
2016
18
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis. ( 27301073 )
2016
19
Abnormalities in the T Cell Receptor VI' Repertoire and Foxp3 Expression in Refractory Anemia with Ringed Sideroblasts. ( 26154600 )
2015
20
Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. ( 25955609 )
2015
21
Myeloid Sarcoma of the Bladder in the Setting of Refractory Anemia with Excess Blasts-2 (RAEB-2). ( 26665895 )
2015
22
Refractory anemia in systemic sclerosis: myelodisplastic syndrome. ( 27708945 )
2015
23
Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association. ( 26133721 )
2015
24
A Case of Refractory Anemia with Excess Blast-2 with Sole Trisomy 13. ( 26299091 )
2015
25
Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia. ( 26457287 )
2015
26
Metastatic Choriocarcinoma of the Small Intestine Presenting as Refractory Anemia and Melena. ( 26157939 )
2015
27
An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report. ( 25621045 )
2015
28
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. ( 25527566 )
2015
29
Dramatic improvement of refractory anemia caused by mechanical hemolysis in a patient with hypertrophic obstructive cardiomyopathy using dual-chamber pacing. ( 26336568 )
2015
30
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). ( 26400023 )
2015
31
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T). ( 25899435 )
2015
32
Severe Refractory Anemia in Primary Intestinal Lymphangiectasia. A Case Report. ( 26405709 )
2015
33
Deferasirox in a refractory anemia after other treatment options: case report and literature review. ( 26185629 )
2015
34
Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts. ( 25709892 )
2015
35
Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation. ( 25963624 )
2015
36
Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. ( 25926061 )
2015
37
Biosimilar epoetin I+ is as effective as originator epoetin-I+ plus liposomal iron (SideralAr), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach. ( 26171179 )
2015
38
A yet unreported der(11)t(6;11)(p21;q21) included in a complex karyotype of a refractory anemia with ring sideroblasts and poor prognosis. ( 24439112 )
2014
39
Refractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T). ( 24575445 )
2014
40
Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. ( 24958999 )
2014
41
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. ( 24476767 )
2014
42
Histopathological evaluation of the bone marrow in refractory anemia with ring sideroblasts and thrombocytosis associated to the JAK2-V617F mutation. ( 24624040 )
2014
43
Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis. ( 23252419 )
2013
44
A case of refractory anemia with ring sideroblasts and associated thrombocytosis. ( 23844433 )
2013
45
Refractory anemia with ring sideroblasts. ( 24507814 )
2013
46
Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapy. ( 24371768 )
2013
47
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. ( 23070040 )
2013
48
Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. ( 23826588 )
2013
49
Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the FAB classification. ( 23897263 )
2013
50
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( 23515411 )
2013

Variations for Refractory Anemia

Expression for Refractory Anemia

Search GEO for disease gene expression data for Refractory Anemia.

Pathways for Refractory Anemia

GO Terms for Refractory Anemia

Biological processes related to Refractory Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin organization GO:0006325 9.58 ASXL1 JAK2 TET2
2 cytokine-mediated signaling pathway GO:0019221 9.54 IL3 JAK2 MPL
3 hemopoiesis GO:0030097 9.43 ASXL1 RUNX1
4 positive regulation of DNA replication GO:0045740 9.32 EPO IL3
5 regulation of cytokine-mediated signaling pathway GO:0001959 9.26 IL3 RUNX1
6 hemoglobin biosynthetic process GO:0042541 9.16 ALAS2 EPO
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.13 EPO IL3 JAK2
8 erythrocyte differentiation GO:0030218 8.8 ALAS2 EPO JAK2

Sources for Refractory Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....